Validations Queue
47,884 candidate doc → node links pending adjudication. Each was auto-generated by cosine similarity ≥ 0.55 between document and prediction embeddings (bge-base-en-v1.5, 768-dim). Showing page 1 of 12, 200 rows by similarity. Adjudicating updates doc_node_links.reviewed=true with the chosen polarity, writes per-link rows to audit_log, and removes the row from this queue. Phase 4 inference will use confirmed corroborates/contradicts links as Bayesian evidence.
Pending (total)
47,884
Reviewed
13
Filtered
2,297
page 1 / 12
Showing on page
200
Filters
URL params control source + min-similarity threshold
Bulk auto-confirm by similarity threshold
Confirm or label (corroborates / contradicts) all unreviewed links above a similarity threshold in one transaction. Each affected row writes a per-link audit_log entry. Capped at 1,000 links per call. Use Preview first.
Source0 selected · 0 visible
Bulk action
| Sim | Doc | Source | Pred | Domain | Prior | |
|---|---|---|---|---|---|---|
| 0.71 | FDA ANDA212336: ANDA212336 ((unspecified)) — DR REDDYS LABS LTD | fda 2026-05-07 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.70 | FDA ANDA214618: LENALIDOMIDE (LENALIDOMIDE) — CIPLA | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.70 | FDA ANDA211182: ANDA211182 ((unspecified)) — HETERO LABS LTD V | fda 2026-04-16 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.69 | FDA NDA220442: NDA220442 ((unspecified)) — SHIONOGI INC | fda 2026-05-29 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.69 | FDA ANDA213093: ANDA213093 ((unspecified)) — QILU PHARM CO LTD | fda 2026-04-29 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.69 | FDA ANDA201452: LENALIDOMIDE (LENALIDOMIDE) — ARROW INTL | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.69 | FDA ANDA216213: LENALIDOMIDE (LENALIDOMIDE) — AMNEAL | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.69 | FDA NDA218197: TRUQAP (CAPIVASERTIB) — ASTRAZENECA | fda 2026-05-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.69 | FDA NDA217180: JAKAFI XR (RUXOLITINIB PHOSPHATE) — INCYTE CORPORATION | fda 2026-05-01 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.69 | FDA NDA020515: ZOLADEX (GOSERELIN) — TERSERA | fda 2026-05-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.69 | FDA ANDA210236: POMALIDOMIDE (POMALIDOMIDE) — HETERO LABS LTD V | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.69 | FDA ANDA220499: ANDA220499 ((unspecified)) — ALEMBIC PHARMACEUTICALS LIMITED | fda 2026-05-13 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.69 | FDA ANDA212414: LENALIDOMIDE (LENALIDOMIDE) — HETERO LABS LTD V | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.68 | FDA ANDA208539: TICAGRELOR (TICAGRELOR) — MICRO LABS | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.68 | FDA ANDA210480: LENALIDOMIDE (LENALIDOMIDE) — ALVOGEN | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.68 | FDA ANDA220421: ANDA220421 ((unspecified)) — HETERO LABS LIMITED, VEMAGAL | fda 2026-05-01 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.68 | FDA ANDA217265: LENALIDOMIDE (LENALIDOMIDE) — QILU | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.68 | FDA ANDA203364: MESNA (MESNA) — RISING | fda 2026-04-09 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.68 | FDA NDA214120: ONUREG (AZACITIDINE) — BRISTOL | fda 2026-04-09 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.68 | FDA ANDA219346: ANDA219346 ((unspecified)) — SANDOZ INC | fda 2026-05-12 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.68 | FDA ANDA217281: LENALIDOMIDE (LENALIDOMIDE) — NOVUGEN | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.68 | FDA NDA217379: NDA217379 ((unspecified)) — FLEX PHARMA, LLC | fda 2026-05-29 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.68 | FDA BLA761070: FASENRA (BENRALIZUMAB) — ASTRAZENECA AB | fda 2026-05-13 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.68 | FDA NDA212576: INQOVI (CEDAZURIDINE) — TAIHO ONCOLOGY | fda 2026-05-13 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.68 | FDA ANDA220143: ANDA220143 ((unspecified)) — HETERO LABS LIMITED | fda 2026-05-22 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.68 | FDA ANDA209348: LENALIDOMIDE (LENALIDOMIDE) — DR REDDYS | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.68 | FDA NDA019726: ZOLADEX (GOSERELIN ACETATE) — TERSERA | fda 2026-05-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.68 | FDA ANDA212975: IMATINIB MESYLATE (IMATINIB MESYLATE) — HETERO LABS LTD V | fda 2026-05-22 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.68 | FDA ANDA220104: MIRTAZAPINE (MIRTAZAPINE) — MICRO LABS | fda 2026-05-19 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.68 | FDA NDA216403: FILSPARI (SPARSENTAN) — TRAVERE | fda 2026-04-13 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.68 | FDA ANDA220221: VERICIGUAT (VERICIGUAT) — TORRENT PHARMACEUTICALS LTD | fda 2026-04-20 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.68 | FDA BLA761055: DUPIXENT (DUPILUMAB) — REGENERON PHARMACEUTICALS | fda 2026-04-22 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA ANDA079162: TOPIRAMATE (TOPIRAMATE) — INVAGEN PHARMS | fda 2026-04-24 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA ANDA207110: BOSENTAN (BOSENTAN) — WATSON LABS INC | fda 2026-04-14 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA NDA207223: DIACOMIT (STIRIPENTOL) — BIOCODEX SA | fda 2026-04-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA ANDA205254: ZOLEDRONIC ACID (ZOLEDRONIC ACID) — MYLAN LABS LTD | fda 2026-04-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA ANDA215356: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — AUROBINDO PHARMA LTD | fda 2026-06-03 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA NDA210655: PERSERIS KIT (RISPERIDONE) — INDIVIOR | fda 2026-04-30 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA ANDA090263: LEVETIRACETAM (LEVETIRACETAM) — CHARTWELL MOLECULAR | fda 2026-04-08 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA ANDA213405: LENALIDOMIDE (LENALIDOMIDE) — TORRENT | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA NDA218316: WEGOVY (SEMAGLUTIDE) — NOVO | fda 2026-05-05 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA BLA761328: BEYFORTUS (NIRSEVIMAB-ALIP) — ASTRAZENECA AB | fda 2026-04-07 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA ANDA073484: VALPROIC ACID (VALPROIC ACID) — BIONPHARMA | fda 2026-04-08 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA ANDA216068: ENZALUTAMIDE (ENZALUTAMIDE) — SANDOZ | fda 2026-04-20 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA ANDA213165: LENALIDOMIDE (LENALIDOMIDE) — CIPLA | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA ANDA214398: LENALIDOMIDE (LENALIDOMIDE) — LUPIN | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA ANDA211545: DAPAGLIFLOZIN (DAPAGLIFLOZIN) — ALKEM LABS LTD | fda 2026-04-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA ANDA213912: LENALIDOMIDE (LENALIDOMIDE) — MYLAN | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA ANDA090508: FINASTERIDE (FINASTERIDE) — SUN PHARM | fda 2026-04-30 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA ANDA204345: CAPECITABINE (CAPECITABINE) — DR REDDYS | fda 2026-05-07 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA ANDA218488: EVEROLIMUS (EVEROLIMUS) — APOTEX | fda 2026-05-12 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA ANDA215243: RAMELTEON (RAMELTEON) — MICRO LABS | fda 2026-04-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA BLA761451: SAPHNELO (ANIFROLIMAB-FNIA) — ASTRAZENECA AB | fda 2026-04-24 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA NDA020578: ZOLADEX (GOSERELIN ACETATE) — TERSERA | fda 2026-05-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA ANDA211026: MACITENTAN (MACITENTAN) — SEASONS BIOTECH | fda 2026-05-19 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA ANDA220264: VERICIGUAT (VERICIGUAT) — CHANGZHOU PHARMACEUTICAL FACTORY | fda 2026-04-08 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA ANDA211506: DAPAGLIFLOZIN (DAPAGLIFLOZIN) — MACLEODS PHARMS LTD | fda 2026-04-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA NDA022433: BRILINTA (TICAGRELOR) — ASTRAZENECA | fda 2026-05-07 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA ANDA078582: LEVETIRACETAM (LEVETIRACETAM) — STRIDES PHARMA | fda 2026-04-21 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA ANDA204741: CAPECITABINE (CAPECITABINE) — AMNEAL PHARMS | fda 2026-05-07 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA ANDA219189: GALLIUM GA-68 GOZETOTIDE (GALLIUM GA-68 GOZETOTIDE) — IONETIX | fda 2026-05-14 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA NDA220482: NDA220482 ((unspecified)) — HAISCO PHARMACEUTICAL GROUP CO LTD | fda 2026-05-29 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA NDA206709: DIACOMIT (STIRIPENTOL) — BIOCODEX SA | fda 2026-04-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA ANDA215336: LEUPROLIDE ACETATE (LEUPROLIDE ACETATE) — AMNEAL | fda 2026-05-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA NDA219249: ITOVEBI (INAVOLISIB) — GENENTECH INC | fda 2026-04-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA ANDA207760: BOSENTAN (BOSENTAN) — ZYDUS PHARMS | fda 2026-04-14 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA ANDA217554: LENALIDOMIDE (LENALIDOMIDE) — DEVA HOLDING AS | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA ANDA211523: DAPAGLIFLOZIN (DAPAGLIFLOZIN) — AIZANT | fda 2026-04-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA ANDA211182: ANDA211182 ((unspecified)) — HETERO LABS LTD V | fda 2026-04-16 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.67 | FDA BLA761069: IMFINZI (DURVALUMAB) — ASTRAZENECA UK LTD | fda 2026-05-28 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA ANDA219257: ANDA219257 ((unspecified)) — RENATA LIMITED | fda 2026-04-08 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA NDA219293: DANZITEN (NILOTINIB TARTRATE) — AZURITY | fda 2026-04-14 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA NDA204026: POMALYST (POMALIDOMIDE) — BRISTOL | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.67 | FDA ANDA220137: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — SOMERSET THERAPS LLC | fda 2026-06-03 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA ANDA211560: DAPAGLIFLOZIN (DAPAGLIFLOZIN) — ALEMBIC | fda 2026-04-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA ANDA217239: TORSEMIDE (TORSEMIDE) — MICRO LABS | fda 2026-05-01 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA BLA761100: ONTRUZANT (TRASTUZUMAB-DTTB) — SAMSUNG BIOEPIS CO LTD | fda 2026-04-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA BLA761352: BIZENGRI (ZENOCUTUZUMAB-ZBCO) — MERUS N.V. | fda 2026-05-08 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA ANDA220274: SODIUM ACETATE (SODIUM ACETATE) — EXTROVIS | fda 2026-04-17 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA ANDA217477: ANDA217477 ((unspecified)) — HAINAN POLY PHARM. CO., LTD. | fda 2026-04-23 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA ANDA215260: SUGAMMADEX (SUGAMMADEX) — TAMARANG SA | fda 2026-05-12 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA ANDA211022: LENALIDOMIDE (LENALIDOMIDE) — APOTEX | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA ANDA200217: LORAZEPAM (LORAZEPAM) — RISING | fda 2026-05-04 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA ANDA211255: LINACLOTIDE (LINACLOTIDE) — ACTAVIS LABS FL INC | fda 2026-05-19 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA ANDA220465: ANDA220465 ((unspecified)) — SANDOZ INC | fda 2026-05-22 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA ANDA090517: VALPROIC ACID (VALPROIC ACID) — QUAGEN | fda 2026-04-17 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA ANDA211846: LENALIDOMIDE (LENALIDOMIDE) — SUN PHARM | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA BLA761111: NYVEPRIA (PEGFILGRASTIM-APGF) — HOSPIRA INC | fda 2026-05-21 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA NDA213756: KOSELUGO (SELUMETINIB SULFATE) — ASTRAZENECA | fda 2026-05-26 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA ANDA081099: METHOTREXATE SODIUM (METHOTREXATE SODIUM) — BARR | fda 2026-05-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA NDA212927: TIOCYSTIN (TIOPRONIN) — CASPER PHARMA LLC | fda 2026-06-02 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA ANDA213405: LENALIDOMIDE (LENALIDOMIDE) — TORRENT | fda 2026-04-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.66 | FDA ANDA210164: POMALIDOMIDE (POMALIDOMIDE) — APOTEX | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA NDA212306: XPOVIO (SELINEXOR) — KARYOPHARM THERAPS | fda 2026-04-30 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA ANDA220444: PALBOCICLIB (PALBOCICLIB) — DR. REDDY'S LABORATORIES LIMITED | fda 2026-05-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA BLA125514: KEYTRUDA (PEMBROLIZUMAB) — MERCK SHARP DOHME | fda 2026-05-12 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA ANDA211156: DAPAGLIFLOZIN (DAPAGLIFLOZIN) — INVENTIA | fda 2026-05-28 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA NDA216993: VANFLYTA (QUIZARTINIB DIHYDROCHLORIDE) — DAIICHI SANKYO INC | fda 2026-04-29 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA ANDA220328: FLUVOXAMINE MALEATE (FLUVOXAMINE MALEATE) — APPCO | fda 2026-04-30 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA NDA019414: CARDIOGEN-82 (RUBIDIUM CHLORIDE RB-82) — BRACCO | fda 2026-05-13 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA ANDA218662: UBROGEPANT (UBROGEPANT) — ZYDUS PHARMACEUTICALS (USA) INC. | fda 2026-05-14 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA ANDA091404: MEROPENEM (MEROPENEM) — ACS DOBFAR | fda 2026-05-20 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA ANDA215356: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — AUROBINDO PHARMA LTD | fda 2026-06-03 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.66 | FDA ANDA212414: LENALIDOMIDE (LENALIDOMIDE) — HETERO LABS LTD V | fda 2026-04-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.66 | FDA NDA215833: PLUVICTO (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN) — NOVARTIS | fda 2026-04-07 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA ANDA209224: LACOSAMIDE (LACOSAMIDE) — AUROBINDO PHARMA LTD | fda 2026-05-22 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA BLA761106: HERCEPTIN HYLECTA (TRASTUZUMAB AND HYALURONIDASE-OYSK) — GENENTECH INC | fda 2026-05-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA ANDA211531: DAPAGLIFLOZIN (DAPAGLIFLOZIN) — LUPIN | fda 2026-04-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA ANDA210435: LENALIDOMIDE (LENALIDOMIDE) — CIPLA | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA ANDA200542: LORAZEPAM (LORAZEPAM) — RISING | fda 2026-05-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA ANDA220041: TOPIRAMATE (TOPIRAMATE) — RICONPHARMA LLC | fda 2026-05-26 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA ANDA213829: LEUPROLIDE ACETATE (LEUPROLIDE ACETATE) — SOMERSET THERAPS LLC | fda 2026-05-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA NDA220837: EVDI (TRABECTEDIN) — APOTEX | fda 2026-05-01 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA ANDA217957: LEUPROLIDE ACETATE (LEUPROLIDE ACETATE) — UBI | fda 2026-05-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA ANDA202420: CALCIUM ACETATE (CALCIUM ACETATE) — CHARTWELL MOLECULAR | fda 2026-05-01 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA ANDA071198: LEUCOVORIN CALCIUM (LEUCOVORIN CALCIUM) — BARR | fda 2026-05-05 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA NDA021732: VANTAS (HISTRELIN ACETATE) — ENDO OPERATIONS | fda 2026-05-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA ANDA220055: ANDA220055 ((unspecified)) — MSN LABORATORIES PRIVATE LIMITED | fda 2026-05-20 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA ANDA210154: LENALIDOMIDE (LENALIDOMIDE) — ZYDUS PHARMS | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.66 | FDA NDA203049: ARGATROBAN (ARGATROBAN) — HIKMA PHARM CO LTD | fda 2026-05-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA BLA761349: COSENTYX (SECUKINUMAB) — NOVARTIS PHARMS CORP | fda 2026-04-17 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA BLA761183: TZIELD (TEPLIZUMAB-MZWV) — PROVENTION BIO INC | fda 2026-04-20 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA220437: TIVOZANIB (TIVOZANIB) — SANDOZ INC | fda 2026-05-14 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA071199: LEUCOVORIN CALCIUM (LEUCOVORIN CALCIUM) — BARR | fda 2026-05-05 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA212336: ANDA212336 ((unspecified)) — DR REDDYS LABS LTD | fda 2026-05-07 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.65 | FDA NDA022561: MAVENCLAD (CLADRIBINE) — EMD SERONO INC | fda 2026-05-14 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA215332: OXCARBAZEPINE (OXCARBAZEPINE) — AUCTA | fda 2026-06-02 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA215575: ANDA215575 ((unspecified)) — QILU PHARM HAINAN | fda 2026-04-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA210386: CANAGLIFLOZIN (CANAGLIFLOZIN) — AUROBINDO PHARMA LTD | fda 2026-04-20 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA NDA020941: ABREVA (DOCOSANOL) — HALEON US HOLDINGS | fda 2026-04-14 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA NDA215256: WEGOVY (SEMAGLUTIDE) — NOVO | fda 2026-05-05 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA220137: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — SOMERSET THERAPS LLC | fda 2026-06-03 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.65 | FDA BLA761309: COLUMVI (GLOFITAMAB-GXBM) — GENENTECH INC | fda 2026-05-28 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA213885: LENALIDOMIDE (LENALIDOMIDE) — EUGIA PHARMA | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA219271: CYCLOPHOSPHAMIDE (CYCLOPHOSPHAMIDE) — HETERO LABS LIMITED | fda 2026-04-29 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA213267: THALIDOMIDE (THALIDOMIDE) — NATCO | fda 2026-04-24 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA091541: LOSARTAN POTASSIUM (LOSARTAN POTASSIUM) — MICRO LABS | fda 2026-04-10 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA213929: LEUCOVORIN CALCIUM (LEUCOVORIN CALCIUM) — LEADING | fda 2026-05-05 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA NDA021488: ELIGARD KIT (LEUPROLIDE ACETATE) — TOLMAR | fda 2026-05-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA BLA761032: SILIQ (BRODALUMAB) — VALEANT LUXEMBOURG | fda 2026-05-07 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA BLA761304: VYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC) — ARGENX BV | fda 2026-05-08 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA BLA761381: OPDIVO QVANTIG (NIVOLUMAB) — BRISTOL-MYERS SQUIBB | fda 2026-05-12 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA200880: ACETAZOLAMIDE SODIUM (ACETAZOLAMIDE SODIUM) — MYLAN ASI | fda 2026-05-07 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA217497: TRETINOIN (TRETINOIN) — AMNEAL | fda 2026-05-14 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA077420: LAMOTRIGINE (LAMOTRIGINE) — RISING | fda 2026-05-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA220043: VORICONAZOLE (VORICONAZOLE) — HAINAN POLY PHARM | fda 2026-05-29 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA211312: DAPAGLIFLOZIN (DAPAGLIFLOZIN) — SANDOZ | fda 2026-04-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA209956: POMALIDOMIDE (POMALIDOMIDE) — TEVA PHARMS USA | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA220326: VILOXAZINE HYDROCHLORIDE (VILOXAZINE HYDROCHLORIDE) — APPCO PHARMA LLC | fda 2026-04-28 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA BLA761468: HEPCLUDEX (BULEVIRTIDE-GMOD) — GILEAD SCIENCES INC | fda 2026-05-22 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA NDA219943: KOSELUGO (SELUMETINIB) — ASTRAZENECA | fda 2026-05-26 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA NDA208400: XATMEP (METHOTREXATE SODIUM) — AZURITY | fda 2026-05-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA210275: POMALIDOMIDE (POMALIDOMIDE) — MYLAN | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA205035: TRANEXAMIC ACID (TRANEXAMIC ACID) — EUGIA PHARMA | fda 2026-04-28 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA071130: HALOPERIDOL (HALOPERIDOL) — AIPING PHARM INC | fda 2026-04-08 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA211533: DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE (DAPAGLIFLOZIN) — MSN | fda 2026-04-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA211563: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — ALKEM LABS LTD | fda 2026-04-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA214216: EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE (EMTRICITABINE) — MACLEODS PHARMS LTD | fda 2026-04-07 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA205402: PALIPERIDONE (PALIPERIDONE) — I3 PHARMS | fda 2026-05-07 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA207740: OMEPRAZOLE (OMEPRAZOLE) — DR REDDYS | fda 2026-04-29 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA211135: RIOCIGUAT (RIOCIGUAT) — MSN | fda 2026-05-08 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA210215: AMANTADINE HYDROCHLORIDE (AMANTADINE HYDROCHLORIDE) — POM PHARMA | fda 2026-05-13 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA NDA202811: LINZESS (LINACLOTIDE) — ABBVIE | fda 2026-05-21 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA NDA018900: METRO I.V. IN PLASTIC CONTAINER (METRONIDAZOLE) — B BRAUN | fda 2026-04-23 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA214956: GABAPENTIN (GABAPENTIN) — ASCENT PHARMS INC | fda 2026-04-24 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA NDA021880: REVLIMID (LENALIDOMIDE) — BRISTOL MYERS SQUIBB | fda 2026-04-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.65 | FDA ANDA219540: GLYCEROL PHENYLBUTYRATE (GLYCEROL PHENYLBUTYRATE) — MSN | fda 2026-04-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA072736: LEUCOVORIN CALCIUM (LEUCOVORIN CALCIUM) — HIKMA | fda 2026-05-05 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA075471: LEUPROLIDE ACETATE (LEUPROLIDE ACETATE) — MEITHEAL | fda 2026-05-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA218691: CEFIXIME (CEFIXIME) — FDC LTD | fda 2026-05-14 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA219869: LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — HETERO LABS LTD V | fda 2026-05-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA NDA214056: ONAPGO (APOMORPHINE HYDROCHLORIDE) — MDD US | fda 2026-05-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA090170: LAMOTRIGINE (LAMOTRIGINE) — UNICHEM LABS LTD | fda 2026-04-09 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA072733: LEUCOVORIN CALCIUM (LEUCOVORIN CALCIUM) — HIKMA | fda 2026-05-05 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA204345: CAPECITABINE (CAPECITABINE) — DR REDDYS | fda 2026-05-07 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.65 | FDA BLA761195: VYVGART (EFGARTIGIMOD ALFA) — ARGENX BV | fda 2026-05-08 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA217265: LENALIDOMIDE (LENALIDOMIDE) — QILU | fda 2026-04-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.65 | FDA ANDA209348: LENALIDOMIDE (LENALIDOMIDE) — DR REDDYS | fda 2026-04-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.65 | FDA ANDA206371: OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — MICRO LABS | fda 2026-04-13 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA215759: LENALIDOMIDE (LENALIDOMIDE) — BIOCON PHARMA | fda 2026-04-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA207974: FINGOLIMOD HYDROCHLORIDE (FINGOLIMOD HYDROCHLORIDE) — ALEMBIC | fda 2026-04-24 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA BLA103792: HERCEPTIN (TRASTUZUMAB) — GENENTECH | fda 2026-05-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA216453: METHOTREXATE SODIUM (METHOTREXATE SODIUM) — ELITE LABS INC | fda 2026-05-27 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA207037: OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — ALKEM LABS LTD | fda 2026-04-23 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA212773: IMATINIB MESYLATE (IMATINIB MESYLATE) — EUGIA PHARMA | fda 2026-04-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA219408: DAPAGLIFLOZIN (DAPAGLIFLOZIN) — SCIEGEN PHARMACEUTICALS INC | fda 2026-04-30 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA218897: VALSARTAN (VALSARTAN) — LAURUS | fda 2026-04-21 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA215759: LENALIDOMIDE (LENALIDOMIDE) — BIOCON PHARMA | fda 2026-04-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.65 | FDA ANDA208055: LURASIDONE HYDROCHLORIDE (LURASIDONE HYDROCHLORIDE) — TORRENT | fda 2026-04-13 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA063065: MINOCYCLINE HYDROCHLORIDE (MINOCYCLINE HYDROCHLORIDE) — WATSON LABS | fda 2026-05-12 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA217432: FAMOTIDINE (FAMOTIDINE) — LUPIN | fda 2026-05-12 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA NDA218197: TRUQAP (CAPIVASERTIB) — ASTRAZENECA | fda 2026-05-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.65 | FDA NDA212102: FINTEPLA (FENFLURAMINE HYDROCHLORIDE) — UCB INC | fda 2026-05-22 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.65 | FDA ANDA211747: OXCARBAZEPINE (OXCARBAZEPINE) — ZYDUS | fda 2026-05-28 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.65 | FDA NDA202293: FARXIGA (DAPAGLIFLOZIN) — ASTRAZENECA AB | fda 2026-06-03 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA208539: TICAGRELOR (TICAGRELOR) — MICRO LABS | fda 2026-04-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.64 | FDA ANDA218441: SITAGLIPTIN (SITAGLIPTIN) — BIOCON PHARMA LTD | fda 2026-05-01 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA NDA209500: CAPLYTA (LUMATEPERONE TOSYLATE) — INTRA-CELLULAR | fda 2026-04-24 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.64 | FDA ANDA214618: LENALIDOMIDE (LENALIDOMIDE) — CIPLA | fda 2026-04-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.64 | FDA ANDA215826: LEUPROLIDE ACETATE (LEUPROLIDE ACETATE) — ZYDUS PHARMS | fda 2026-05-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% |